Figure 6.

Bufalin and MK2206 inhibited MM cell growth in vivo. Mice bearing murine-derived MOPC315 MM tumors were treated with bufalin (1 mg/kg; intraperitoneally) daily in the presence and/or absence of MK2206 (120 mg/kg orally) for 10 days. Mice injected with human-derived H929 MM cells were treated with 1 mg/kg bufalin daily with or without 120 mg/kg MK2206 for 12 days. Tumor volume (a and d) and the weight of mice (b and e) were measured every 2 days. The tumor volume was calculated using the following formula: V=(length × width²)/2 (mean tumor volume±S.D., 3 mice per group). (c and f) Tumor sections from four groups were subjected to immunostaining using TUNEL and anti-Ki67 Abs that demonstrated tumor cell apoptosis and proliferation. Experiments were performed in triplicate (*P<0.05)